AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
3 reports, 3 independent
Updated Sep 4
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.Sub-event
Joint development of Epkinly for DLBCL treatment announced.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Genmab
Danish healthcare company
-
Sarah Cannon Research Institute
research institute in Nashville, Tennessee, USA
Nothing else this week.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaAbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial AbbVie and Genmab’s subcutaneous Epkinly (epcoritamab) has proved to be viable as an outpatient treatment in a Phase II trial.
- ZacksABBV's Improving Oncology Sales Poise It Well for Long-Term Growth AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira. However, AbbV
- Pharmaceutical TechnologyEpkinly breaks ground in Phase III FL trial Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in relap